Rockefeller Capital Management L.P. Boosts Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Rockefeller Capital Management L.P. grew its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 250,410 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,006 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Jazz Pharmaceuticals were worth $30,838,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in JAZZ. Centre Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the fourth quarter valued at about $9,335,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $464,000. Franklin Resources Inc. grew its position in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 13.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after acquiring an additional 4,332 shares in the last quarter. Finally, Sanctuary Advisors LLC boosted its stake in Jazz Pharmaceuticals by 502.8% in the third quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock valued at $1,310,000 after acquiring an additional 9,804 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on JAZZ shares. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. HC Wainwright increased their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Morgan Stanley restated an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Royal Bank of Canada lowered their target price on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $187.71.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CMO Robert Iannone sold 7,080 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company’s stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,736 shares of company stock worth $4,023,305. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.5 %

Shares of Jazz Pharmaceuticals stock opened at $100.50 on Monday. The stock has a market cap of $6.10 billion, a PE ratio of 14.15, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42. The firm has a fifty day moving average price of $129.67 and a 200 day moving average price of $122.77. Jazz Pharmaceuticals plc has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.